AzTrials
AzTrials

Kidney TransplantationTrasplanCEUNCT07923188

Online Exercise Program for Transplant Patients: A Pilot Study

A study testing Online Therapeutic Exercise Programme in people with Kidney Transplantation and Physical Function, run by Cardenal Herrera University at 1 site in Spain.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

Kidney transplant recipients frequently experience reduced physical function, muscle weakness, low levels of physical activity, and an increased risk of cardiovascular and metabolic complications, despite improvements in survival and quality of life following transplantation. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Online Therapeutic Exercise Programme
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteSpain
Study dates
1 Nov 2026to 14 May 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults aged 18 years or older.
  • Kidney transplant recipients.
  • At least 12 months post-transplantation.
  • Sufficient cognitive capacity to understand study instructions and provide informed consent.
  • Ability to monitor heart rate and blood pressure at home.
  • Ability to connect remotely and participate in synchronous online exercise sessions.

Who cannot join

  • Physical or clinical limitations that prevent safe participation in the exercise programme, such as severe cardiovascular instability.
  • Severe psychopathology or serious cognitive impairment.
  • Specific medical contraindications to participation in the exercise programme.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Spain1 site
  • Universities Carden Herrera CEU

    Valencia, Valencia, 46115

Other trials in Spain

About this study

Kidney transplant recipients frequently experience reduced physical function, muscle weakness, low levels of physical activity, and an increased risk of cardiovascular and metabolic complications, despite improvements in survival and quality of life following transplantation. Therapeutic exercise has been shown to improve cardiorespiratory fitness, muscle strength, and physical function in this population. However, access to supervised rehabilitation programmes after transplantation remains limited. Online exercise programmes may provide an accessible and feasible alternative, particularly for patients who face geographical or logistical barriers to attending supervised in-person sessions.

Read the detailed description

This pilot randomized controlled trial aims to evaluate the feasibility and safety of a supervised group-based online therapeutic exercise programme for transplant recipients. Participants will be randomly allocated to either a control group receiving usual care or an intervention group participating in a supervised online exercise programme. Secondary outcomes will include muscle strength, physical function, physical activity, sarcopenia, frailty, muscle characteristics, anthropometric measures, body composition, and biochemical parameters.

Being tested
Online Therapeutic Exercise Programme, Usual Care Control Group
Keywords
Kidney transplantation, Therapeutic exercise, Online exercise, Muscle strength, Physical activity, Sarcopenia, Frailty
Medical subject headings
Motor Activity, Sarcopenia, Frailty

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Online Therapeutic Exercise ProgrammeBehavioural

    Participants will complete three supervised online exercise sessions per week for 24 weeks. Each session will last approximately 30-40 minutes and will include lower-limb resistance exercises targeting the major muscle groups, brisk walking intervals, and progressive balance exercises. Exercise difficulty will be individualized by the physiotherapist according to perceived exertion. Heart rate, blood pressure, and rating of perceived exertion will be monitored during the intervention.

  • Usual Care Control GroupBehavioural

    Participants randomized to the control group will maintain their usual activities and standard care throughout the 24-week intervention period. They will not receive the supervised online therapeutic exercise intervention.

Study groups in NCT07923188
Study groupRoleWhat they receive
Online Exercise GroupExperimentalParticipants allocated to the intervention group will participate in a supervised group-based online therapeutic exercise programme delivered via Microsoft Teams for 24 weeks.
Receives: Behavioral: Online Therapeutic Exercise Programme
Usual Care Control GroupActive comparatorParticipants allocated to the control group will continue with their usual activities and usual care throughout the 24-week study period and will not participate in the supervised online therapeutic exercise programme.
Receives: Behavioral: Usual Care Control Group

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Recruitment Rate

    The percentage of eligible individuals who are enrolled in the study.

    Measured: During the recruitment period, up to 2 months

  2. Adherence to the Online Exercise Programme

    Adherence will be calculated as the percentage of exercise sessions completed by each participant relative to the total number of sessions scheduled during the 24-week intervention.

    Measured: Throughout the 24-week intervention

  3. Participant Retention Rate

    The percentage of enrolled participants who complete the final study assessment relative to the total number of participants initially enrolled.

    Measured: At 24 weeks

  4. Number of Adverse Events During the Exercise Programme

    Safety will be assessed by recording adverse events occurring during exercise sessions, including musculoskeletal injuries, cardiovascular symptoms, exercise intolerance, or any event requiring modification or temporary suspension of the intervention.

    Measured: Throughout the 24-week intervention

Secondary outcomes (25)
  1. Lower-Limb Muscle Strength Assessed by Hand-Held Dynamometry

    Maximal isometric strength of the hip flexors and hip abductors will be assessed using hand-held dynamometry. Three maximal voluntary contractions will be performed for each muscle group, and the maximum value will be recorded in kilogram-force (kgf).

    Measured: Baseline, 4 weeks, 3 months, and 6 months

  2. Handgrip Strength

    Handgrip strength will be assessed using a Jamar® hydraulic dynamometer. Three maximal voluntary contractions will be performed with each hand, and the maximum value will be recorded in kilograms (kg).

    Measured: Baseline, 3 months, and 6 months

  3. 60-Second Sit-to-Stand Test Performance

    Functional capacity will be assessed using the 60-Second Sit-to-Stand Test (STS-60). The total number of complete sit-to-stand repetitions performed within 60 seconds will be recorded. A higher number of repetitions indicates better functional performance.

    Measured: Baseline, 3 months, and 6 months

  4. Timed Up and Go Test Performance

    Functional mobility and dynamic balance will be assessed using the Timed Up and Go (TUG) test. The time required to stand from a chair, walk 3 metres, turn, return, and sit down will be recorded in seconds.

    Measured: Baseline, 3 months, and 6 months

  5. 6-Minute Walk Test Distance

    Walking capacity will be assessed using the 6-Minute Walk Test (6MWT). The total distance walked during 6 minutes will be recorded in metres (m).

    Measured: Baseline, 3 months, and 6 months

  6. Physical Activity Assessed by the Human Activity Profile

    Physical activity will be assessed using the Human Activity Profile (HAP). The Adjusted Activity Score (AAS) will be recorded.

    Measured: Baseline, 3 months, and 6 months

  7. Change in Risk of Sarcopenia Assessed by SARC-F

    Risk of sarcopenia will be assessed using the SARC-F questionnaire. The total score ranges from 0 to 10, with a score ≥4 indicating risk of sarcopenia.

    Measured: Baseline, 3 months, and 6 months

  8. Frailty Assessed by the FRAIL Scale

    Frailty will be assessed using the FRAIL scale. Scores range from 0 to 5, with a score ≥3 indicating frailty.

    Measured: Baseline, 3 months, and 6 months

  9. Rectus Femoris Muscle Characteristics Assessed by Ultrasound

    Musculoskeletal ultrasound will be used to assess rectus femoris muscle thickness (mm), cross-sectional area (cm²), and muscle echogenicity.

    Measured: Baseline, 3 months, and 6 months

  10. Anthropometric Measurements

    Waist circumference, upper-arm circumference, and calf circumference will be measured using standardised procedures and recorded in centimetres (cm).

    Measured: Baseline, 3 months, and 6 months

  11. Body Composition Assessed by Bioelectrical Impedance Vector Analysis

    Body composition will be assessed using bioelectrical impedance vector analysis (BIVA), including muscle mass.

    Measured: Baseline, 3 months, and 6 months

  12. T3

    Triiodothyronine (T3) is the primary biologically active form of thyroid signaling molecules. Measures both bound and free T3 combined. (ng/dL)

    Measured: Baseline, 3 months, and 6 months

  13. T4

    Thyroxine (T4) is one of the two main hormones produced by the thyroid gland.(mcg/dL)

    Measured: Baseline, 3 months, and 6 months

  14. Testosterone

    Testosterone is the primary male sex hormone (androgen), although it is also present and essential in females in much smaller amounts. It is a steroid hormone synthesized primarily from cholesterol; (ng/dL :nanograms per deciliter)

    Measured: Baseline, 3 months, and 6 months

  15. Cortisol

    Cortisol is a steroid hormone produced by the adrenal glands (located on top of each kidney) that is essential for life and regulates a wide range of vital processes throughout the body.

    Measured: Baseline, 3 months, and 6 months

  16. Estrogens

    Estrogens are a group of hormones crucial for sexual and reproductive development, primarily in women.Estrogen levels are typically measured via a blood test and reported in picograms per milliliter (pg/mL) or picomoles per liter (pmol/L).

    Measured: Baseline, 3 months, and 6 months

  17. Progesterone

    Progesterone is an endogenous 21-carbon steroid hormone derived from cholesterol. It is primarily classified as a progestogen (the main one in the human body) and plays a fundamental role in regulating the menstrual cycle, supporting early pregnancy, and promoting embryogenesis.

    Measured: Baseline, 3 months, and 6 months

  18. Fasting glucose

    Fasting glucose (glicemia a digiuno) is a blood test that measures the amount of sugar (glucose) in your blood after an overnight fast (usually 8 to 12 hours without eating or drinking anything except water). It is primarily used to screen for and diagnose prediabetes and diabetes.Fasting glucose is typically measured in milligrams per deciliter (mg/dL) or millimoles per liter (mmol/L).

    Measured: Baseline, 3 months, and 6 months

  19. Creatinine

    Creatinine is a waste product produced by muscles from the breakdown of a compound called creatine. Your kidneys filter creatinine from your blood and excrete it through urine. Measuring creatinine levels is the most common way to assess how well your kidneys are functioning.Milligrams per deciliter (mg/dL).

    Measured: Baseline, 3 months, and 6 months

  20. Estimated glomerular filtration rate

    The Estimated Glomerular Filtration Rate (eGFR) is a blood test that estimates how well your kidneys are filtering waste. It is the primary metric used by medical professionals to determine your level of kidney function and to stage Chronic Kidney Disease (CKD). The measurement is reported in milliliters per minute per 1.73 square meters of body surface area (mL/min/1.73 m²).

    Measured: Baseline, 3 months, and 6 months

  21. C-reactive protein

    C-reactive protein (CRP) is a protein made by the liver that increases when there is active inflammation or infection in the body.CRP is typically measured in milligrams per liter (mg/L) or milligrams per deciliter (mg/dL).

    Measured: Baseline, 3 months, and 6 months

  22. Albumin

    Albumin is the most abundant circulating protein found in blood plasma, representing about 50% to 60% of all plasma proteins. Synthesized exclusively by the liver, it performs two vital biological functions: maintaining oncotic pressure (which keeps fluid from leaking out of blood vessels into surrounding tissues) and transporting molecules like hormones, fatty acids, bilirubin, medications, and ions throughout the body. Normal Adult Reference Range: 3.4 to 5.4 g/dL (grams per deciliter) or 34 to 54 g/L (grams per liter).

    Measured: Baseline, 3 months, and 6 months

  23. Total cholesterol

    Total cholesterol is a measurement of the total amount of cholesterol in your blood. It is a waxy, fat-like substance that your body needs to build healthy cells, but having too much of it can increase your risk of heart disease.mg/dL (milligrams per deciliter).

    Measured: Baseline, 3 months, and 6 months

  24. A Complete Blood Count (CBC)

    A Complete Blood Count (CBC) is a standard blood test that evaluates your overall health and detects a wide range of disorders, including anemia, infection, and leukemia. It measures the three primary types of cells in your blood: red blood cells, white blood cells, and platelets.

    Measured: Baseline, 3 months, and 6 months

  25. Albuminuria

    Albuminuria is a pathological condition characterized by the abnormal presence of albumin-a primary plasma protein-in the urine. (mg/day)

    Measured: Baseline, 3 months, and 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Nov 2026
  2. Study start1 Nov 2026 (estimated)
  3. Primary completion14 May 2027 (estimated)
  4. Study completion14 May 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07923188
Sponsor's protocol ID
TrasplanCEU
Acronym
TrasplanCEU
Status last verified
Oct 2026
First submitted
26 Oct 2026
Last updated
6 Nov 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Wang W. Optimizing Quality of Life in Kidney Transplant Recipients Through Structured Exercise: A Systematic Review and Evidence-Based Guidelines. Med Sci Monit. 2024 Jul 24;30:e943617. doi: 10.12659/MSM.943617.

    PubMed 39044393
  • Pape L, Boeck HT, Boyen J, Nohre M, Schiffer L, Kuck M, Schieffer E, Albrecht A, de Zwaan M, Tegtbur U, Schiffer M, Haufe S. Physical activity and exercise performance in patients after kidney transplantation - Data from the prospective KTx360 degrees aftercare program. J Sci Med Sport. 2025 Nov;28(11):938-945. doi: 10.1016/j.jsams.2025.06.012. Epub 2025 Jul 5.

    PubMed 40681408
  • Knobbe TJ, Kremer D, Zelle DM, Klaassen G, Dijkema D, van Vliet IMY, Leurs PB, Bemelman FJ, Christiaans MHL, Berger SP, Navis G, Bakker SJL, Corpeleijn E. Effect of an exercise intervention or combined exercise and diet intervention on health-related quality of life-physical functioning after kidney transplantation: the Active Care after Transplantation (ACT) multicentre randomised controlled trial. Lancet Healthy Longev. 2024 Sep;5(9):100622. doi: 10.1016/j.lanhl.2024.07.005. Epub 2024 Sep 10.

    PubMed 39270688
  • Billany RE, Macdonald JH, Burns S, Chowdhury R, Ford EC, Mubaarak Z, Sohansoha GK, Vadaszy N, Young HML, Bishop NC, Smith AC, Graham-Brown MPM. A structured, home-based exercise programme in kidney transplant recipients (ECSERT): A randomised controlled feasibility study. PLoS One. 2025 Feb 24;20(2):e0316031. doi: 10.1371/journal.pone.0316031. eCollection 2025.

    PubMed 39992959
  • doi:10.1080/0886022X.2025.2480246

Questions about this trial

What is this clinical trial studying?

A study testing Online Therapeutic Exercise Programme in people with Kidney Transplantation and Physical Function, run by Cardenal Herrera University at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Recruitment Rate (time frame: During the recruitment period, up to 2 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07923188, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in